— Know what they know.
Not Investment Advice
Also trades as: AVTR-PA (NYSE) · $vol 18M

AVTR NYSE

Avantor, Inc.
1W: +3.0% 1M: +11.9% 3M: +19.0% YTD: +49.3% 1Y: +11.1% 3Y: -16.7% 5Y: -55.2%
$17.13
-0.16 (-0.93%)
 
Weekly Expected Move ±3.6%
$16 $17 $17 $18 $19
NYSE · Healthcare · Medical - Instruments & Supplies · Tech Score Strong Buy · Power 70 · $11.6B mcap · 658M float · 1.42% daily turnover · Short 53% of daily vol
Credit Risk of going bust: higher than 58% of companies Debt: 24.2% of company value Bonds: $264.2M held by 222 funds, 108 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.53 (down 97%), Avantor, Inc. would be worth roughly what it owes.
Total debt $3.70B against a stock market value of $11.59B.
Distance to default 4.35 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.87B (short-term plus half of long-term), stock volatility 50.8%; Altman Z 1.97. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Supply Chain Overview

3 relationships
3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-09-16
Earliest Filing
2021-09-16
Latest Filing
partner: 2 target: 1

Counterparties (Filed by AVTR)

3 relationships

Companies named in AVTR's SEC 8-K filings as business counterparties.

Counterparty Ticker Relationship Summary Filing Date SEC
Goldman Sachs & Co. LLC GSCE partner Underwriter for the common stock offering 2021-09-16 View
Citigroup Global Markets Inc. — partner Underwriter for the common stock offering 2021-09-16 View
Antylia Scientific — target Target of the announced acquisition of the Masterflex bioprocessing business 2021-09-16 View
Recent 8-K Filings (20)
Filing Date Description Type SEC
2026-09-21 Officer/Director Change; Regulation FD; Exhibits View
2026-09-21 Officer/Director Change; Regulation FD; Exhibits View
2026-08-27 Officer/Director Change; Exhibits View
2026-07-29 Earnings Release; Exhibits View
2026-07-17 Material Agreement; Financial Obligation; Exhibits Agreement View
2026-05-12 Shareholder Vote; Exhibits View
2026-04-29 Earnings Release; Exhibits View
2026-04-23 Officer/Director Change; Regulation FD; Exhibits View
2026-04-01 Officer/Director Change; Regulation FD; Exhibits View
2026-02-25 Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits View
2026-02-25 Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits View
2026-02-11 Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex View
2025-12-18 Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem View
2025-12-04 Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem View
2025-11-10 Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem View
2025-10-29 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2025-10-14 Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem View
2025-10-14 Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of Agreement View
2025-10-03 Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem View
2025-08-13 Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms